EUVIMEDEUVIMED entdecken
EvaluationsstudieOpen Access · CC BY 4.0

A novel single-tier serologic test to diagnose all stages of Lyme disease

Andrew E Levin iD, Gary P Wormser iD, Elizabeth J Horn, Nadezhda Karaseva, Drew Miller, Hunter Kellogg

Journal of Clinical Microbiology · 2025

DOI: 10.1128/jcm.00483-25 ↗

Kurz gefasst

Evaluationsstudie in der Zeitschrift Journal of Clinical Microbiology, 2025. Verfasst von Andrew E Levin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Kephera Diagnostics, LLCFramingham, Massachusetts, USA. Hauptthemen laut MEDLINE: Lyme Disease, Antibodies, Bacterial, Serologic Tests, Borrelia burgdorferi. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lyme disease, a bacterial zoonosis, is the most commonly reported vector-borne disease in the United States. Laboratory diagnosis has relied on a two-tier serologic approach, originally comprising an ELISA, or another first-tier assay, followed by separate IgG and IgM immunoblots to confirm a positive first-tier result. This standard two-tier testing (STTT) approach provides high specificity, but at the cost of low sensitivity in early Lyme disease. Recent studies have shown that a modified two-tier (MTTT) testing approach, in which a second ELISA replaces the immunoblot, can provide an increase in test sensitivity without a loss of specificity. Nevertheless, neither STTT nor MTTT is considered sensitive enough for diagnosing patients with erythema migrans, the most common clinical manifestation of early Lyme disease. We have developed a novel ELISA methodology termed “Hybrid Lyme ELISA” for single-tier Lyme antibody detection, which relies on the simultaneous binding of individual antibody molecules to the Borrelia burgdorferi surface protein VlsE and to the C6 peptide derived from it. This dual binding requirement builds exceptionally high specificity into the assay, eliminating the majority of non-specific antibody interactions. In this study, the single-tier Hybrid Lyme ELISA was shown to provide greater sensitivity, but with equivalent specificity, to both STTT and MTTT. In addition, given the >90% sensitivity of the Hybrid Lyme ELISA in patients with erythema migrans, this assay may not only transform serologic testing from two-step to single-step testing, but may also provide a means for the first time to diagnose patients with erythema migrans. IMPORTANCE The diagnosis of Lyme disease, a tick-borne spirochetal infection caused by Borrelia burgdorferi sensu lato, is subject to two major limitations: the need for a two-tier serologic testing algorithm to provide adequate specificity, and the low sensitivity of this algorithm in practice for detection of early Lyme disease manifesting with the erythema migrans skin lesion, the most common clinical manifestation. This study presents the first description of a new assay, the Hybrid Lyme ELISA, which demonstrates sensitivity high enough to potentially diagnose over 90% of patients with erythema migrans, and specificity high enough to preclude the need for a second-tier test. These test characteristics suggest the potential for the Hybrid Lyme ELISA to be the first single-tier serologic test suitable for laboratory diagnosis of all stages of Lyme disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lyme DiseaseAntibodies, BacterialSerologic TestsBorrelia burgdorferiHumansSensitivity and SpecificityEnzyme-Linked Immunosorbent AssayAntigens, BacterialLipoproteinsBacterial ProteinsImmunoglobulin GImmunoglobulin MFemaleAdultMale

Stichwörter der Autor:innen

Borrelia burgdorferiLyme diseasediagnosisserologytwo-tier serology

Substanzen

Antibodies, BacterialAntigens, BacterialVlsE protein, Borrelia burgdorferiLipoproteinsBacterial ProteinsImmunoglobulin GImmunoglobulin M

Autor:innen und Institutionen

  • Kephera Diagnostics, LLCFramingham, Massachusetts, USA.
  • Division of Infectious Diseases, Department of Medicine, New York Medical College, Valhalla, New York, USA.
  • Lyme Disease BiobankPortland, Oregon, USA.

ORCID-Profile: Andrew E Levin, Gary P Wormser

Förderung

  • NIAID NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Levin, A. E., Wormser, G. P., Horn, E. J., Karaseva, N., Miller, D., & Kellogg, H. (2025). A novel single-tier serologic test to diagnose all stages of Lyme disease. Journal of Clinical Microbiology. https://doi.org/10.1128/jcm.00483-25

Vancouver

Levin AE, Wormser GP, Horn EJ, Karaseva N, Miller D, Kellogg H. A novel single-tier serologic test to diagnose all stages of Lyme disease. Journal of Clinical Microbiology. 2025. doi:10.1128/jcm.00483-25

BibTeX
@article{Levin2025,
  author = {Levin, Andrew E and Wormser, Gary P and Horn, Elizabeth J and Karaseva, Nadezhda and Miller, Drew and Kellogg, Hunter},
  title = {A novel single-tier serologic test to diagnose all stages of Lyme disease},
  journal = {Journal of Clinical Microbiology},
  year = {2025},
  doi = {10.1128/jcm.00483-25}
}
Kostenlos starten →